Repligen to Report Fourth Quarter and Full Year 2025 Financial Results
Rhea-AI Summary
Repligen (NASDAQ:RGEN) will report fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. A press release will be issued before market open and management will host a conference call at 8:30 a.m. ET to discuss results for periods ended December 31, 2025.
The live call is toll-free at (800) 715-9871 (U.S.) or (646) 307-1963 (international) with no passcode. A webcast and subsequent replay will be available in the company Investor Relations section of the website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, RGEN declined 0.36%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
RGEN is up 0.98% with slightly elevated volume, while key peers show mixed moves: STVN up 5.09%, ATR up 3.66%, TFX, BLCO, and MMSI down modestly. With only one peer in the momentum scanner and no common news, the move appears stock-specific around the earnings date announcement.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 06 | Board leadership change | Neutral | +1.7% | Announcement of chair transition and advisor role through March 2027. |
| Dec 18 | Investor conference | Neutral | +0.5% | Presentation scheduled at J.P. Morgan 2026 Healthcare Conference. |
| Dec 16 | Product launch | Positive | -1.6% | Introduction of three new chromatography resins for next‑gen modalities. |
| Nov 26 | Conference participation | Neutral | -0.3% | Planned participation in 8th Annual Evercore Healthcare Conference. |
| Nov 04 | Multiple conferences | Neutral | -2.2% | Series of November 2025 investor conference appearances with webcasts. |
Recent news has mostly seen price moves align with neutral corporate updates, with one instance where positive product news was followed by a negative reaction.
Over the past few months, RGEN’s news flow has focused on governance, investor outreach, and product innovation. A board leadership change announced on Jan 6, 2026 coincided with a 1.66% gain. Multiple conference participation announcements in Nov–Dec 2025 produced modest moves around zero. A notable exception was the launch of next‑generation chromatography resins on Dec 16, 2025, where shares fell 1.55% despite the positive product update. Today’s earnings date notice fits within this cadence of scheduled corporate communications.
Market Pulse Summary
This announcement schedules RGEN’s fourth quarter and full year 2025 results for February 24, 2026, with a conference call at 8:30 a.m. ET. It follows several months of routine corporate updates such as conference appearances and governance changes. Ahead of the call, investors may focus on how forthcoming numbers compare with prior communications and on any commentary that might reframe recent insider selling and the stock’s position above its 200-day moving average.
AI-generated analysis. Not financial advice.
Webcast and Conference Call to Be Held Tuesday, February 24, 2026, at 8:30 a.m. ET
WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter 2025 financial results on Tuesday, February 24, 2026. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and twelve- month reporting periods ended December 31, 2025.
The conference call will be accessible by dialing toll-free (800) 715-9871 for domestic callers and (646) 307-1963 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. You can access the replay on the Investor Relations section of Company’s website.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at www.repligen.com, and follow us on LinkedIn.
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
Repligen Contact:
Jacob Johnson
VP, Investor Relations
(781) 419-0204
investors@repligen.com
FAQ
When will Repligen (RGEN) release its Q4 and FY2025 financial results?
How can investors join the Repligen (RGEN) earnings conference call on February 24, 2026?
Will Repligen (RGEN) provide a webcast and replay for the February 24, 2026 call?
What periods will Repligen (RGEN) discuss during the February 24, 2026 call?
Is a passcode required to access Repligen (RGEN)'s February 24, 2026 earnings call?
